Pacira BioSciences, Inc. (PCRX) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Pacira BioSciences, Inc. (PCRX) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry, with a market capitalization near $906.3M, listed on NASDAQ, employing roughly 788 people, carrying a beta of 0.32 to the broader market. Pacira BioSciences, Inc. Led by Frank D. Lee, public since 2011-02-03.
Snapshot as of May 15, 2026.
- Spot Price
- $22.80
- Max Pain Strike
- $27.50
- Total OI
- 1.7K
As of May 15, 2026, Pacira BioSciences, Inc. (PCRX) max pain sits at $27.50, which is above the current spot price of $22.80 (20.6% away). Spot sits 20.6% above max pain - the gap is wide enough that the pinning effect alone is unlikely to close it; expect catalyst flow, positioning unwinds, or rebalancing to drive the actual price path before any expiration pull. PCRX is a low-priced underlying (spot $22.80), where $0.50 or finer strike spacing increases the number of viable pin candidates and dampens the dominant-strike effect. Total open interest across the listed chain is comparatively thin (1.7K contracts), so single-strike pinning is less reliable than it is for high-OI names. PCRX is currently in positive dealer gamma ($3.0K), the regime that mechanically reinforces pinning by inducing dealers to buy weakness and sell strength near heavy-OI strikes. Max pain identifies the strike at which the aggregate dollar value of all outstanding options contracts would expire with the least total intrinsic value, a gravitational reference rather than a price target.
PCRX Strategy Implications at the Current Max Pain Level
With spot 20.6% from the $27.50 max-pain level and Pacira BioSciences, Inc. in a positive-gamma regime, where dealer hedging mechanically pulls spot toward heavy-OI strikes, strategy selection turns on cycle position and dealer positioning. Iron condors and credit spreads centered near the max-pain strike capture the typical end-of-cycle convergence when the regime supports pinning; ratio backspreads or directional debit structures fit names where catalyst flow is likely to overwhelm the hedging-driven pull. The gamma-exposure page shows the per-strike dealer book that determines whether hedging will reinforce or fight the pin.
Learn how max pain is reported and how to read the data →
Frequently asked PCRX max pain analysis questions
- What is the current PCRX max pain strike?
- As of May 15, 2026, Pacira BioSciences, Inc. (PCRX) max pain sits at $27.50, which is 20.6% above the current spot price of $22.80. Max pain identifies the strike at which aggregate option-buyer payouts at expiration are minimized; it is a gravitational reference, not a price target. A 20.6% gap is wide enough that the pinning effect alone is unlikely to close it; expect catalyst flow, positioning unwinds, or rebalancing to drive the price path before any expiration pull.
- Does PCRX pin to its max pain strike at expiration?
- PCRX is currently in positive dealer gamma, the regime that mechanically reinforces pinning. Dealers hedging long-gamma books buy weakness and sell strength near high-OI strikes, which pulls spot toward those levels into expiration. Total open interest across PCRX (1.7K contracts) is one input to how plausible a clean pin is - heavier total OI concentrated at fewer strikes raises the probability; thin OI spread across many strikes lowers it. Pinning is strongest in heavily-traded names with large open-interest concentrations at high-OI strikes during the final week of an OPEX cycle. Whether PCRX actually pins on a given expiration depends on the OI distribution, the dealer-gamma sign, and the absence of catalyst-driven moves that overwhelm hedging-driven flow.
- How is PCRX max pain calculated?
- Max pain is computed by summing the dollar value of all in-the-money options at each candidate settlement strike across listed expirations, then selecting the strike that minimizes total intrinsic-value payout to option buyers. The calculation uses the full open-interest distribution and weighs both calls and puts. PCRX put/call OI ratio is 0.28 - call-heavy, which biases the max-pain calculation toward strikes above current spot when the call OI concentrates there.